![taeyeon fine sungha jung tabs taeyeon fine sungha jung tabs](http://1.bp.blogspot.com/-x1Yu_KcgC0c/VkoHIw6Rx9I/AAAAAAAACZs/R49EwDiBMi8/s1600/Rainy%2BDay%2B%28Sungha%2BJung%29.png)
![taeyeon fine sungha jung tabs taeyeon fine sungha jung tabs](http://i1.ytimg.com/vi/QhBj1FS5sXY/0.jpg)
Objectives To determine the effectiveness of fixed-dose combination therapy on reducing fatal and non-fatal CVD events and on improving blood pressure and lipid CVD risk factors for both primary and secondary prevention of CVD. A fixed-dose combination of blood pressure and cholesterol lowering and antiplatelet treatments into a single pill, or polypill, has been proposed as one strategy to reduce the global burden of CVD by up to 80% given its potential for better adherence and lower costs. PMID:25267903ĭe Cates, Angharad N Farr, Matthew RB Wright, Nicola Jarvis, Morag C Rees, Karen Ebrahim, Shah Huffman, Mark Dīackground Cardiovascular disease (CVD) is the leading cause of death and disability worldwide, yet CVD risk factor control and secondary prevention rates remain low. This will include studies conducted in both developed and developing regions of the world. We will also determine any adverse events associated with taking fixed-dose combination therapy.
![taeyeon fine sungha jung tabs taeyeon fine sungha jung tabs](https://i.ytimg.com/vi/oFoocRF5Ro8/mqdefault.jpg)
Details of CVD events and risk factors included are listed in the methods. The objectives are as follows: To determine the effectiveness of fixed-dose combination therapy on optimising CVD risk factors and reducing CVD fatal and non-fatal events for both primary and secondary prevention of CVD. This is the protocol for a review and there is no abstract. Fixed-dose combination therapy for the prevention of cardiovascular diseaseĭe Cates, Angharad N Farr, Matthew RB Rees, Karen Casas, Juan P Huffman, Mark